Clinical Trials Browser

Lymphoma, Large B-Cell, Diffuse × orelabrutinib × 90 days × Clear all

NCT07499271 2026-03-30

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse